HUP0103507A3 - Pharmaceutical compositions comprising 2-quinolones - Google Patents
Pharmaceutical compositions comprising 2-quinolonesInfo
- Publication number
- HUP0103507A3 HUP0103507A3 HU0103507A HUP0103507A HUP0103507A3 HU P0103507 A3 HUP0103507 A3 HU P0103507A3 HU 0103507 A HU0103507 A HU 0103507A HU P0103507 A HUP0103507 A HU P0103507A HU P0103507 A3 HUP0103507 A3 HU P0103507A3
- Authority
- HU
- Hungary
- Prior art keywords
- quinolones
- pharmaceutical compositions
- pharmaceutical
- compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9809060A FR2781218B1 (fr) | 1998-07-15 | 1998-07-15 | Compositions pharmaceutiques comprenant des 2-quinolones |
PCT/FR1999/001716 WO2000003990A1 (fr) | 1998-07-15 | 1999-07-13 | Compositions pharmaceutiques comprenant des 2-quinolones |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0103507A2 HUP0103507A2 (hu) | 2002-02-28 |
HUP0103507A3 true HUP0103507A3 (en) | 2002-05-28 |
Family
ID=9528650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0103507A HUP0103507A3 (en) | 1998-07-15 | 1999-07-13 | Pharmaceutical compositions comprising 2-quinolones |
Country Status (22)
Country | Link |
---|---|
US (1) | US6593342B1 (hu) |
EP (1) | EP1097138B1 (hu) |
JP (1) | JP2002520394A (hu) |
KR (1) | KR20010071859A (hu) |
CN (1) | CN1195740C (hu) |
AT (1) | ATE312080T1 (hu) |
AU (1) | AU766282B2 (hu) |
BR (1) | BR9912073A (hu) |
CA (1) | CA2337115A1 (hu) |
CZ (1) | CZ2001148A3 (hu) |
DE (1) | DE69931925D1 (hu) |
EA (1) | EA003933B1 (hu) |
FR (1) | FR2781218B1 (hu) |
HU (1) | HUP0103507A3 (hu) |
IL (1) | IL140437A0 (hu) |
NO (1) | NO319771B1 (hu) |
NZ (1) | NZ509076A (hu) |
PL (1) | PL345550A1 (hu) |
SK (1) | SK162001A3 (hu) |
TR (1) | TR200100075T2 (hu) |
WO (1) | WO2000003990A1 (hu) |
ZA (1) | ZA200100235B (hu) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001293233A1 (en) | 2000-09-01 | 2002-03-13 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
EP1650203B1 (en) | 2000-09-11 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
FR2813791B1 (fr) | 2000-09-14 | 2004-03-12 | Lafon Labor | Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale |
AU2003288899B2 (en) | 2002-08-23 | 2009-09-03 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
BR0316229A (pt) | 2002-11-13 | 2005-10-04 | Chiron Corp | Métodos de tratamento de câncer e métodos relacionados |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US7960548B2 (en) * | 2005-04-29 | 2011-06-14 | The Ohio State University Research Foundation | Keratinocyte growth factor receptor—tyrosine specific inhibitors for the prevention of cancer metastatis |
JP5545925B2 (ja) | 2005-05-17 | 2014-07-09 | ノバルティス アーゲー | ヘテロ環化合物の合成方法 |
US20090048276A1 (en) * | 2006-01-30 | 2009-02-19 | Goulet Mark T | Inhibitors of Fatty Acid Synthase (Fas) |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
EP1860104A1 (en) * | 2006-05-22 | 2007-11-28 | Aptanomics | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
CN101801951B (zh) | 2007-09-14 | 2013-11-13 | 杨森制药有限公司 | 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮 |
EP2200985B1 (en) | 2007-09-14 | 2011-07-13 | Ortho-McNeil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
ES2330495B1 (es) * | 2007-11-07 | 2010-09-20 | Consejo Superior De Investigaciones Cientificas (Titular Al 51%) | Inhibidores de la enzima o6-alquilguanina-adn-metil-transferasa para el tratamiento del cancer. |
ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
US8691813B2 (en) | 2008-11-28 | 2014-04-08 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MX2011011962A (es) | 2009-05-12 | 2012-02-28 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2). |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
ME01573B (me) | 2009-05-12 | 2014-09-20 | Addex Pharma Sa | DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA |
AU2011328195B2 (en) | 2010-11-08 | 2015-04-02 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
CN103242231B (zh) * | 2013-05-21 | 2015-10-28 | 天津青松华药医药有限公司 | 喹啉类衍生物及其制备方法与应用 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
KR20200036063A (ko) | 2014-01-21 | 2020-04-06 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
MX2018007361A (es) | 2015-12-17 | 2019-05-16 | Biokine Therapeutics Ltd | Moléculas pequeñas para inhibir la actividad de quimiocinas, la actividad de una cinasa y/o el crecimiento de células cancerosas. |
EP3390378B1 (en) | 2015-12-17 | 2022-03-30 | AlonBio Ltd. | Small molecules against cancer |
KR101879992B1 (ko) * | 2016-07-29 | 2018-07-19 | 국립암센터 | c-Myc/Max/DNA 복합체 형성을 억제하는 화합물 |
CN114096524A (zh) | 2019-05-15 | 2022-02-25 | 阿龙拜欧有限公司 | 用于治疗癌症、抑制趋化因子活性和/或诱导细胞死亡的小分子 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2249217A1 (de) * | 1972-10-07 | 1974-04-18 | Hoechst Ag | Verfahren zum faerben von synthetischen fasermaterialien aus organischen loesemitteln |
EP0024638A1 (en) * | 1979-08-30 | 1981-03-11 | Byk Gulden Lomberg Chemische Fabrik GmbH | Substituted quinolinone-alkanecarboxylic acids, their preparation, and medicaments containing them |
GB9125515D0 (en) * | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
AU4780793A (en) * | 1992-07-22 | 1994-02-14 | Genelabs Technologies, Inc. | 2-aryl-4-quinolones as antitumor compounds |
ES2088822B1 (es) * | 1994-02-24 | 1997-08-01 | Univ Madrid Complutense | Nuevos derivados antraquinonicos con actividad antitumoral y sus aplicaciones. |
US5726184A (en) * | 1995-05-19 | 1998-03-10 | Vertex Pharmaceuticals Incorporated | Tetralin compounds with improved MDR activity |
-
1998
- 1998-07-15 FR FR9809060A patent/FR2781218B1/fr not_active Expired - Fee Related
-
1999
- 1999-07-13 HU HU0103507A patent/HUP0103507A3/hu unknown
- 1999-07-13 NZ NZ509076A patent/NZ509076A/en unknown
- 1999-07-13 US US09/743,766 patent/US6593342B1/en not_active Expired - Fee Related
- 1999-07-13 AT AT99931343T patent/ATE312080T1/de not_active IP Right Cessation
- 1999-07-13 TR TR2001/00075T patent/TR200100075T2/xx unknown
- 1999-07-13 IL IL14043799A patent/IL140437A0/xx unknown
- 1999-07-13 CZ CZ2001148A patent/CZ2001148A3/cs unknown
- 1999-07-13 AU AU47891/99A patent/AU766282B2/en not_active Ceased
- 1999-07-13 DE DE69931925T patent/DE69931925D1/de not_active Expired - Lifetime
- 1999-07-13 EA EA200100139A patent/EA003933B1/ru not_active IP Right Cessation
- 1999-07-13 KR KR1020017000476A patent/KR20010071859A/ko not_active Application Discontinuation
- 1999-07-13 BR BR9912073-9A patent/BR9912073A/pt not_active Application Discontinuation
- 1999-07-13 SK SK16-2001A patent/SK162001A3/sk unknown
- 1999-07-13 CN CNB998085820A patent/CN1195740C/zh not_active Expired - Fee Related
- 1999-07-13 PL PL99345550A patent/PL345550A1/xx not_active Application Discontinuation
- 1999-07-13 JP JP2000560097A patent/JP2002520394A/ja active Pending
- 1999-07-13 CA CA002337115A patent/CA2337115A1/en not_active Abandoned
- 1999-07-13 EP EP99931343A patent/EP1097138B1/fr not_active Expired - Lifetime
- 1999-07-13 WO PCT/FR1999/001716 patent/WO2000003990A1/fr not_active Application Discontinuation
-
2001
- 2001-01-09 ZA ZA200100235A patent/ZA200100235B/en unknown
- 2001-01-12 NO NO20010228A patent/NO319771B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000003990A1 (fr) | 2000-01-27 |
NO20010228D0 (no) | 2001-01-12 |
EA200100139A1 (ru) | 2001-06-25 |
EP1097138B1 (fr) | 2005-12-07 |
IL140437A0 (en) | 2002-02-10 |
SK162001A3 (en) | 2002-04-04 |
CN1309639A (zh) | 2001-08-22 |
PL345550A1 (en) | 2001-12-17 |
EA003933B1 (ru) | 2003-10-30 |
CN1195740C (zh) | 2005-04-06 |
DE69931925D1 (de) | 2006-07-27 |
CA2337115A1 (en) | 2000-01-27 |
US6593342B1 (en) | 2003-07-15 |
NO20010228L (no) | 2001-03-15 |
ATE312080T1 (de) | 2005-12-15 |
JP2002520394A (ja) | 2002-07-09 |
BR9912073A (pt) | 2001-04-10 |
NZ509076A (en) | 2003-10-31 |
ZA200100235B (en) | 2002-01-09 |
EP1097138A1 (fr) | 2001-05-09 |
AU4789199A (en) | 2000-02-07 |
FR2781218A1 (fr) | 2000-01-21 |
HUP0103507A2 (hu) | 2002-02-28 |
NO319771B1 (no) | 2005-09-12 |
KR20010071859A (ko) | 2001-07-31 |
FR2781218B1 (fr) | 2001-09-07 |
AU766282B2 (en) | 2003-10-16 |
TR200100075T2 (tr) | 2001-08-21 |
CZ2001148A3 (cs) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP9901606A2 (en) | Pharmaceutical compositions comprising sildenaphil | |
HUP0103507A3 (en) | Pharmaceutical compositions comprising 2-quinolones | |
GB9827996D0 (en) | Pharmaceutical Compositions | |
GB9727053D0 (en) | Pharmaceutical compositions | |
PL343627A1 (en) | Medicinal compositions | |
PT1466615E (pt) | Composição farmacêutica | |
CY2569B1 (en) | Pharmaceutical compositions | |
PL343769A1 (en) | Pharmaceutical composition | |
GB9809213D0 (en) | Pharmaceutical compositions | |
GB9818591D0 (en) | Pharmaceutical composition | |
IL131995A0 (en) | Gastric-retained pharmaceutical compositions | |
GB9723985D0 (en) | Pharmaceutical compositions | |
HUP0004669A3 (en) | Pharmaceutical compositions | |
EP1124557A4 (en) | PHARMACEUTICAL COMPOSITION | |
IL137403A0 (en) | Pharmaceutical compositions | |
HU9700632D0 (en) | Pharmaceutical compositions | |
GB9806487D0 (en) | Pharmaceutical compositions | |
ZA982117B (en) | Pharmaceutical compositions | |
HU9800078D0 (en) | Pharmaceutical composition | |
GB9827441D0 (en) | Pharmaceutical compositions | |
GB9814818D0 (en) | Pharmaceutical compositions | |
GB9818953D0 (en) | Pharmaceutical compositions | |
GB9826821D0 (en) | Pharmaceutical compositions | |
GB9826822D0 (en) | Pharmaceutical compositions | |
GB9827006D0 (en) | Pharmaceutical compositions |